GLP-1 Receptor Agonists Are Safe in Women with Benign Parathyroid Tumors
GLP-1 receptor agonists can be prescribed to a woman with a history of benign parathyroid tumors without contraindication, as there is no established association between these medications and parathyroid disease or malignancy.
Key Evidence on GLP-1 RAs and Cancer Risk
The primary safety concern with GLP-1 RAs relates to thyroid cancer (specifically medullary thyroid carcinoma), not parathyroid tumors:
The most recent and comprehensive meta-analysis of 48 randomized controlled trials involving 94,245 participants found that GLP-1 RAs probably have little or no effect on thyroid cancer risk (OR 1.37,95% CI 0.82-2.31), with moderate certainty of evidence 1.
A 2025 international multisite cohort study of 98,147 GLP-1 RA users across six countries found no association between GLP-1 RA use and thyroid cancer (pooled weighted HR 0.81,95% CI 0.59-1.12) over median follow-up of 1.8-3.0 years 2.
A large Scandinavian cohort study (145,410 GLP-1 RA users) similarly found no increased thyroid cancer risk (HR 0.93,95% CI 0.66-1.31) over mean follow-up of 3.9 years 3.
Why Parathyroid Tumors Are Not a Concern
Parathyroid adenomas are entirely distinct from thyroid tissue and have no biological relationship to GLP-1 receptor signaling:
Parathyroid adenomas are benign tumors of the parathyroid glands that cause primary hyperparathyroidism through autonomous PTH production, affecting approximately 80% of hyperparathyroidism cases 4.
The theoretical thyroid cancer concern with GLP-1 RAs stems from rodent studies showing C-cell hyperplasia and medullary thyroid carcinoma (which arises from thyroid C-cells), not parathyroid tissue 5.
There is no biological mechanism, preclinical data, or clinical evidence linking GLP-1 RAs to parathyroid tumor development, growth, or recurrence 1, 6.
Clinical Application
Prescribe GLP-1 RAs based on standard indications without modification for benign parathyroid history:
For patients with type 2 diabetes and established cardiovascular disease, GLP-1 RAs should be considered to reduce major adverse cardiovascular events regardless of HbA1c 4.
For patients with type 2 diabetes and high cardiovascular risk (age ≥55 with arterial stenosis >50%, left ventricular hypertrophy, eGFR <60, or albuminuria), GLP-1 RAs can be considered for MACE reduction 4.
For obesity management in adults without diabetes, GLP-1 RAs demonstrate significant efficacy: semaglutide 2.4 mg weekly produces up to 13.9% weight loss, and tirzepatide 15 mg weekly produces up to 17.8% weight loss 7.
Important Caveats
The only thyroid-related contraindication is personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2):
MEN2A can include both medullary thyroid carcinoma and parathyroid adenomas as part of the syndrome 4.
If the patient's parathyroid adenoma occurred in the context of MEN2A syndrome, GLP-1 RAs are contraindicated due to the MEN2 association, not the parathyroid tumor itself 5.
If the parathyroid adenoma was sporadic (not part of MEN syndrome), proceed with GLP-1 RA therapy without restriction 4.